Professor Stephen Gough joins Novo Nordisk as senior principal clinical scientist
pharmafile | October 2, 2015 | Appointment | Medical Communications, Research and Development | Novo Nordisk, Professor Stephen Gough
Novo Nordisk has announced that Professor Stephen Gough, a renowned clinical and research specialist in diabetes, joined the company today as senior principal clinical scientist.
In his new role in Denmark, Professor Gough will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to Phase III and beyond for the treatment of diabetes and obesity. He will remain as a visiting professor of diabetes and fellow of Harris Manchester College, Oxford University, where he will continue to lead on joint activities with Novo Nordisk, supervise research and provide input into clinical services.
Professor Gough comments: “I am excited to join a company with over 90 years of dedication to finding better treatments for diabetes. I look forward to working with the exceptional scientific team at Novo Nordisk to help translate research into meaningful therapies that make a difference for patients.”
Professor Gough joins Novo Nordisk from the Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM). At Oxford, he led active diabetes research groups with a focus on the genetics of autoimmunity. He is also a member of the UK National Welcome Trust Case Control Consortium for genetic studies in common diseases.
While at Oxford University, Professor Gough helped develop translational research within OCDEM focusing on novel agents for type 1 and type 2 diabetes and beta cell replacement therapy.
He was previously professor of medicine at the University of Birmingham and consultant physician with a special interest in diabetes at the University Hospitals and Birmingham National Health Service Foundation Trust.
Dr Alan Moses, global chief medical officer, Novo Nordisk, says: “Novo Nordisk can only stay at the forefront of research and development in diabetes and obesity through the recruitment of exceptional scientists and clinicians. With his key clinical expertise, his experience as a researcher focused on patient issues, and his compassion for patients with diabetes, Professor Gough will have a vital role in working toward Novo Nordisk’s ambition of changing diabetes.”
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
